Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Xerostomia 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Radiation Injuries 1Prostatic Neoplasms 1Mucositis 1Lung Neoplasms 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Bevacizumab 112Fluorouracil 98Oxaliplatin 96Leucovorin 96Irinotecan 86Capecitabine 73Cetuximab 64Panitumumab 42pembrolizumab 38regorafenib 28Nivolumab 23IFL protocol 22Folfox protocol 21trifluridine tipiracil drug combination 14Radiotherapy 13durvalumab 11Gemcitabine 10Celecoxib 10tremelimumab 7binimetinib 7aflibercept 7Drug Therapy 7Disulfides 7Cyclophosphamide 7Trifluridine 6Trastuzumab 6Sunitinib 6Paclitaxel 6Immunoglobulin G 6Colonoscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colorectal Neoplasms × Selenomethionine × Clear all
NCT00625183 2017-11-17

Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

Roswell Park Cancer Institute

Phase 2 Terminated
5 enrolled 6 charts
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡